Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Efficacy of Tapering Biologics and JAK Inhibitors in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis, Eficacia de la reducción gradual de biológicos e inhibidores de JAK en la artritis reumatoide: una revisión sistemática y metaanálisi

  • Rotea-Salvo, Sandra
  • Galindo, Laura
  • Acasuso, Belén
  • Balboa-Barreiro, Vanesa
  • Ramudo Cela, Luis
  • Silva-Díaz, Maite
  • Oreiro Villar, Natividad
  • De-Toro, Javier
  • Martín-Herranz, Isabel
  • Blanco García, Francisco J
Review, [Abstract] Objective. This study assessed the evidence on the efficacy of tapering anti-TNF, JAK inhibitors, and tocilizumab in patients with rheumatoid arthritis (RA). Methods. In February 2024, a systematic review was conducted by searching Medline, Embase, Web of Sciences, and the Cochrane Library for randomized controlled trials comparing the efficacy of tapering vs standard treatment. The outcomes evaluated were the maintenance of low disease activity (LDA), remission, and flare-ups. A meta-analysis was conducted when data were available. The risk of bias was assessed using RoB 2. The study was registered on PROSPERO and conducted in accordance with the PRISMA guidelines. Results. A total of 2861 records were identified, with 1638 records screened after removing duplicates. Finally, fifteen studies involving 2782 patients were included. Follow-up ranged from 6 months to 3.5 years. Tapering anti-TNF did not affect LDA maintenance while showing a lower probability of maintaining remission (RR 0.69, 95% CI 0.57–0.84) and a higher risk of flare-ups (RR 1.96, 95% CI 1.57–2.45). Tapering JAK inhibitors showed a decreased probability of maintaining LDA (RR 0.83, 95% CI 0.76–0.91) and remission (RR 0.86, 95% CI 0.75–0.99), and more frequent and earlier flares. Tapering tocilizumab also resulted in a lower probability of maintaining LDA or remission and a higher risk of flares. Several included studies presented a risk of bias, mainly related to outcome measurement and open-label designs. Conclusion. Although tapering anti-TNF did not affect LDA maintenance, due to the increased risk of flare-ups and reduced remission probability, routine dose tapering of anti-TNF, JAK inhibitors, and tocilizumab for patients with RA is not recommended in all of them. Identifying patients who may benefit from tapering is crucial., [Resumen] Objetivos. Este estudio evaluó la evidencia sobre la eficacia de la reducción gradual de anti-TNF, inhibidores de JAK y tocilizumab en pacientes con artritis reumatoide (AR). Métodos. En febrero de 2024, se realizó una revisión sistemática buscando en Medline, Embase, Web of Sciences y la Biblioteca Cochrane ensayos controlados aleatorizados que compararan la eficacia de la reducción gradual frente al tratamiento estándar. Los resultados evaluados fueron el mantenimiento de la actividad baja de la enfermedad (ABE), la remisión y los brotes (flare-ups). Se realizó un metaanálisis cuando hubo datos disponibles. El riesgo de sesgo se evaluó utilizando RoB 2. El estudio fue registrado en PROSPERO y se llevó a cabo de acuerdo con las directrices PRISMA. Resultados. Se identificó un total de 2861 registros, y se cribaron 1638 registros después de eliminar los duplicados. Finalmente, se incluyeron quince estudios que involucraron a 2782 pacientes. El seguimiento osciló entre 6 meses y 3,5 años. La reducción gradual de anti-TNF no afectó el mantenimiento de ABE, pero mostró una menor probabilidad de mantener la remisión (RR 0,69, IC 95% 0,57-0,84) y un mayor riesgo de brotes (RR 1,96, IC 95% 1,57-2,45). La reducción gradual de inhibidores de JAK mostró una probabilidad disminuida de mantener ABE (RR 0,83, IC 95% 0,76-0,91) y la remisión (RR 0,86, IC 95% 0,75-0,99), y brotes más frecuentes y tempranos. La reducción gradual de tocilizumab también resultó en una menor probabilidad de mantener ABE o remisión y un mayor riesgo de brotes. Varios de los estudios incluidos presentaron un riesgo de sesgo, principalmente relacionado con la medición de los resultados y con diseños abiertos. Conclusión. Aunque la reducción gradual de anti-TNF no afectó el mantenimiento de ABE, debido al mayor riesgo de brotes y a la reducción de la probabilidad de remisión, no se recomienda la reducción rutinaria de la dosis de anti-TNF, inhibidores de JAK y tocilizumab para todos los pacientes con AR. Identificar a los pacientes que pueden beneficiarse de la reducción gradual es crucial., This work has been funded partially by Instituto de Salud Carlos III (ISCIII) by the grant PMP22/00101 and RICORSREI-RD21/0002/0009, European Union-NextGeneration EUPlan de Recuperación transformación y resiliencia and by grant IN607A2021/07 from Xunta de Galicia. SR was supported by ISCIII Programa Rio Hortega CM22/00210 and LG was supported by Catedra FSR-UDC.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Integrated Serum Proteomics and Autoantibody Analyses Reveal a Biomarker Signature Predictive of Flare During Biologic Tapering in Rheumatoid Arthritis

  • Blanco García, Francisco J
  • Quaranta, Patricia
  • Domínguez-Guerrero, Pablo
  • Calamia, Valentina
  • Fernández-Puente, Patricia
  • Paz González, Rocío
  • Balboa-Barreiro, Vanesa
  • Noriega-Cobo, Diana M.
  • Galindo, Laura
  • Acasuso, Belén
  • Oreiro Villar, Natividad
  • Rojo, Ricardo
  • Lourido, Lucía
  • Ruiz-Romero, Cristina
[Abstract] Background: Reliable biomarkers predicting which patients with rheumatoid arthritis (RA) can safely undergo biologic tapering are currently lacking. This study aimed to identify circulating protein biomarkers predictive of flare during biologic disease-modifying anti-rheumatic drug tapering in RA. Methods: Baseline serum samples from patients with RA in sustained remission enrolled in the Biologic Optimisation (OPTIBIO) clinical trial were analysed using a two-stage design comprising an exploratory mass spectrometry in a discovery sample subset (n=44, 22 in the optimisation arm and 22 in the control arm), followed by ELISA validation of selected protein biomarkers and anti-cytokine autoantibody profiling in the full cohort (n=194). The primary outcome was a disease flare during follow-up. Results: During follow-up, disease flare occurred in 46.4% of patients in the optimisation arm and 30.9% in the control arm. Within the discovery subset of the optimisation arm, 87 proteins were differentially abundant between patients who flared and those who remained in remission. V-set immunoglobulin-domain-containing 4 (VSIG4) was validated as a biomarker associated with increased flare risk while anti-interferon-γ (anti-IFNγ) autoantibodies were also independently associated with flare. A combined model integrating VSIG4, anti-IFNγ and Disease Activity Score 28-joint count using C reactive protein improved discrimination compared with the clinical model alone (area under the curve (AUC) 0.760 vs 0.666) and showed higher sensitivity and greater potential clinical utility in decision curve analysis. In a secondary exploratory subgroup of patients with prolonged remission, predictive performance further improved (AUC 0.839). Conclusion: These findings identify a promising protein biomarker signature associated with flare during biologic tapering in RA, supporting biomarker-guided risk stratification in treatment optimisation strategies. External validation is required before clinical implementation., This work was supported by the Instituto de Salud Carlos III (ISCIII) through the projects PI20/00793, PI22/01155, PMP22/00101 and PI23/00818 (to FJB and CRR) and co-funded by the European Union. Additional funding was provided by Xunta de Galicia (grants IN607D2020/10, IN607A2021/07, and IN607A2025/11). LL was supported by a Sara Borrell Fellowship (CD19/00229). VC is supported by grant RD24/00070026, funded by the Carlos III Health Institute (ISCIII) and co-financed by the European Union. RPG is supported by Programa de axudas á etapa posdoutoral from Xunta de Galicia (IN606B-2024.22). The Biomedical Research Networking Center (CIBER) is an initiative of ISCIII (CB06/01/0040). This study has been also supported by an Open Access Articles grant from Fundación Pública Galega de Investigación Biomédica INIBIC.